109 related articles for article (PubMed ID: 24201236)
1. Curcumin as an add-on to antidepressive treatment.
Pae CU
Clin Neuropharmacol; 2013; 36(6):242-3. PubMed ID: 24201236
[No Abstract] [Full Text] [Related]
2. Curcumin as an add-on to antidepressive treatment: a randomized, double-blind, placebo-controlled, pilot clinical study.
Bergman J; Miodownik C; Bersudsky Y; Sokolik S; Lerner PP; Kreinin A; Polakiewicz J; Lerner V
Clin Neuropharmacol; 2013; 36(3):73-7. PubMed ID: 23673908
[TBL] [Abstract][Full Text] [Related]
3. Curcumin as a putative antidepressant.
Seo HJ; Wang SM; Han C; Lee SJ; Patkar AA; Masand PS; Pae CU
Expert Rev Neurother; 2015 Mar; 15(3):269-80. PubMed ID: 25644944
[TBL] [Abstract][Full Text] [Related]
4. The Role of Curcumin Administration in Patients with Major Depressive Disorder: Mini Meta-Analysis of Clinical Trials.
Al-Karawi D; Al Mamoori DA; Tayyar Y
Phytother Res; 2016 Feb; 30(2):175-83. PubMed ID: 26610378
[TBL] [Abstract][Full Text] [Related]
5. Curcumin and major depression: a randomised, double-blind, placebo-controlled trial investigating the potential of peripheral biomarkers to predict treatment response and antidepressant mechanisms of change.
Lopresti AL; Maes M; Meddens MJ; Maker GL; Arnoldussen E; Drummond PD
Eur Neuropsychopharmacol; 2015 Jan; 25(1):38-50. PubMed ID: 25523883
[TBL] [Abstract][Full Text] [Related]
6. Investigation of the efficacy of adjunctive therapy with bioavailability-boosted curcuminoids in major depressive disorder.
Panahi Y; Badeli R; Karami GR; Sahebkar A
Phytother Res; 2015 Jan; 29(1):17-21. PubMed ID: 25091591
[TBL] [Abstract][Full Text] [Related]
7. Multiple antidepressant potential modes of action of curcumin: a review of its anti-inflammatory, monoaminergic, antioxidant, immune-modulating and neuroprotective effects.
Lopresti AL; Hood SD; Drummond PD
J Psychopharmacol; 2012 Dec; 26(12):1512-24. PubMed ID: 23035031
[TBL] [Abstract][Full Text] [Related]
8. Chronic Supplementation of Curcumin Enhances the Efficacy of Antidepressants in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Pilot Study.
Yu JJ; Pei LB; Zhang Y; Wen ZY; Yang JL
J Clin Psychopharmacol; 2015 Aug; 35(4):406-10. PubMed ID: 26066335
[TBL] [Abstract][Full Text] [Related]
9. Antidepressant effects of curcumin and HU-211 coencapsulated solid lipid nanoparticles against corticosterone-induced cellular and animal models of major depression.
He X; Zhu Y; Wang M; Jing G; Zhu R; Wang S
Int J Nanomedicine; 2016; 11():4975-4990. PubMed ID: 27757031
[TBL] [Abstract][Full Text] [Related]
10. Successful Treatment of Major Depressive Disorder With Add-On Buprenorphine in a Patient With Previous Nonresponse to Standard Antidepressants.
Elsayed M; Gahr M; Connemann BJ; Schönfeldt-Lecuona C
Prim Care Companion CNS Disord; 2017 Sep; 19(5):. PubMed ID: 28972704
[No Abstract] [Full Text] [Related]
11. [Clinical experiences with the antidepressive agent Nortrilene].
Melliwa H
Hippokrates; 1965 Oct; 36(19):755-8. PubMed ID: 5863924
[No Abstract] [Full Text] [Related]
12. Curcumin for neuropsychiatric disorders: a review of in vitro, animal and human studies.
Lopresti AL
J Psychopharmacol; 2017 Mar; 31(3):287-302. PubMed ID: 28135888
[TBL] [Abstract][Full Text] [Related]
13. Atypical antipsychotic augmentation in treatment-resistant major depressive disorder.
Delgado A; Ehert M
Conn Med; 2011 Mar; 75(3):153-6. PubMed ID: 21500706
[No Abstract] [Full Text] [Related]
14. Emerging drugs for major depressive disorder: an update.
Rizvi SJ; Kennedy SH
Expert Opin Emerg Drugs; 2012 Sep; 17(3):285-94. PubMed ID: 22530790
[No Abstract] [Full Text] [Related]
15. Protriptyline in the treatment of depressive reactions.
Oltman JE; Friedman S
Am J Psychiatry; 1965 Nov; 122(5):582-4. PubMed ID: 5835833
[No Abstract] [Full Text] [Related]
16. [Personality test and prediction of antidepressive treatment effect in mental illness].
Nielsen S
Ugeskr Laeger; 2010 Mar; 172(13):1068; author reply 1068. PubMed ID: 20411601
[No Abstract] [Full Text] [Related]
17. Milnacipran treatment of a terminally ill cancer patient with major depressive disorder.
Sato K; Higuchi H; Yoshida K; Takahashi H; Shimizu T; Watanabe J
Hum Psychopharmacol; 2004 Aug; 19(6):431-2. PubMed ID: 15303248
[No Abstract] [Full Text] [Related]
18. Organising the front line: Is there a rationale for the first-line pharmacotherapy of major depressive disorder?
Baune BT; Boyce P; Morris G; Hamilton A; Bassett D; Hopwood M; Mulder R; Parker G; Porter R; Singh AB; Outhred T; Das P; Malhi GS
Aust N Z J Psychiatry; 2019 Apr; 53(4):279-281. PubMed ID: 30813748
[No Abstract] [Full Text] [Related]
19. [Results of treatment of depressive states with melitracen].
Madejska N; Mika M; Pańkow T
Psychiatr Pol; 1967; 1(4):463-71. PubMed ID: 5595168
[No Abstract] [Full Text] [Related]
20. Management of major depressive disorder in primary care.
Dantz B
Mich Med; 2008; 107(3):24-6. PubMed ID: 18700401
[No Abstract] [Full Text] [Related]
[Next] [New Search]
